Viruses cells


Developing quality therapeutic
cGMP protein and vaccine solutions
in the international contract market
for preclinical through to Phase III
clinical supply.
DNA



Production Systems

  • CHO
  • HEK293
  • Baculovirus
  • Drosophila S2
  • NSO

Stirred tank, perfusion, roller bottle and hollow fibre technologies
 

Cell Line Development

  • Molecular biology:
  • Cloning (any gene from any source)
  • Expression vector development
  • maxXpress Service:
    • Rapid mammalian protein production, UCOE
  • Qualified strains:
    • Sf9 & Hi5 (Baculovirus)
    • CHO
    • Drosophila S2
    • GS-CHO hybridomas
    • Myelomas
    • PER.C6
  • Stability testing to ICH guidelines
  • Vector development: free to use and proprietary systems

Process Development & Scale Up

  • Development of robust and scaleable processes
  • Media development and optimisation (animal component free)
  • Optimisation of harvest parameters to improve both quality and productivity
  • Development of efficient extraction and primary recovery procedures
  • Chromatographic purification
  • Formulation

Analytical Development & Validation

  • Analytical development
  • Analytical validation to ICH guidelines
  • Cleaning validation
  • Stability testing to ICH guidelines
  • Raw material testing
  • Assay Transfer
  • Shipping Studies
Analytical methods include:

(In-house)
  • reverse phase chromatography
  • ion exchange chromatography
  • size exclusion chromatography
  • western blot
  • activity assays/cell based potency
  • PCR/QPCR
  • SDS-PAGE horizontal & vertical
  • IEF
  • spectrometry- (UV/IR/visible)
  • fluorimetry
  • capillary electrophoresis
  • peptide mapping
  • LAL
  • bioburden
  • ELISA
  • residual host DNA/Protein
(Out-sourced)
  • Mass spectrometry
  • Amino acid analysis
  • Amino acid sequencing

cGMP Manufacturing

  • Master Cell Bank & Working Cell Bank production
  • Cell bank characterisation
  • Pre-clinical & clinical supply

Primary / Secondary Labelling

  • Primary labelling (or re-labelling) of drug product vials for human clinical centres
  • Secondary packaging and labelling of vials for dispatch to clinical centres
  • Tertiary and transport labelling & packaging as required
  • Guidance on regulatory requirements and details of primary and secondary labels
  • Fully traceable clinical labelling to batch records, under QA observation with QP review and issue of cGMP Certificate of Compliance.
  • Phase I and Phase II labelling supporting clinical trials worldwide
  • Regulatory documents review as required to support release to clinic

Quality Assurance & Regulatory Support

  • Three Qualified Persons (QP)
  • Fully compliant with European Clinical Trials Directive 2001/20/EC and FDA standards
  • Authorised by UK MHRA for the GMP of Investigational Medicinal Products (IMPs)
  • Support clients with their CMC filings, and will support clients at face-to-face agency meetings
  • QP release
  • Shipment to clinical trial sites
  • Representation at MHRA and FDA meetings to support client programmes
  • Process and facility validation advice services
  • GXP consultancy for clients

Project Management

Cobra recognises the importance of trust and transparency between you the client and your dedicated Cobra project manager in every project.

Maintaining clear lines of communication with regular client interaction significantly lessens risk and the chance of time delays.

We believe that a project’s success depends on the delivery of a quality final product from a multi-functional project team on schedule and within budget. Combining our scientific expertise with this project management style is the foundation for building client trust and the reason clients return for future projects.

It is this attitude matched with over 15 years of industry experience that ensures Cobra delivers quality in every aspect of the process, from project conception to product delivery.


Facilities & Capacity

Keele
Facility area ft2 m2
Process development 4,200 390
Class 10,000 clean rooms    2,400 223
Class 100,000 clean rooms    1,500 139
QC 2,000 186
Stores 1,700 158
Plant 5,800 539
     
Total 24,000 2,583
     
Oxford    
Facility area ft2 m2
Process development 700 65 
Class 1,000 clean rooms 54 10
Class 10,000 clean rooms 1,871 174
Class 100,000 clean rooms    2,469 229
QC 81 8
Stores 1,313 122
Plant 2,368 220
     
Total 16,000 1,722
     
Protein Manufacture
Upstream: 2 x 7L, 1 x 20L Stirred Tank 
  1 x 20L, 2 x 30L, 1 x 100L Stirred Tank/Perfusion
  50L Disposable System (Capacity for larger systems)
   
Downstream: Modular/Disposable Systems:
  -  Manual Chromatography Disposable Flow Path
  -  Ultra Filtration/Diafiltration Tangential Flow Filtration Systems
  -  Disposable Filtration Systems
  Hardware:
  -  BPG Columns (up to 300mm diameter)
  -  UV Flow Cells (5mm path length)
  -  AKTA Purifier / Explorer / Pilot / Process
“We have been impressed by the experience Cobra brings to the table and look forward to a mutually beneficial collaboration."

David G. Watumull
President and CEO,
Hawaii Biotech

Cobra’s first Phase III product manufactured was a protein

   

 

News Alert

View privacy policy